Financial Analysis: National Research (NRC) vs. Its Rivals
National Research (NASDAQ: NRC) is one of 33 public companies in the “Commercial physical research” industry, but how does it compare to its rivals? We will compare National Research to related companies based on the strength of its earnings, dividends, analyst recommendations, profitability, risk, valuation and institutional ownership.
Valuation & Earnings
This table compares National Research and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|National Research||$119.69 million||$30.05 million||62.39|
|National Research Competitors||$1.17 billion||$41.39 million||17.64|
This table compares National Research and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|National Research Competitors||-364.60%||-19.77%||-13.43%|
National Research pays an annual dividend of $0.76 per share and has a dividend yield of 1.2%. National Research pays out 73.1% of its earnings in the form of a dividend. As a group, “Commercial physical research” companies pay a dividend yield of 1.2% and pay out 73.1% of their earnings in the form of a dividend.
Institutional & Insider Ownership
35.5% of National Research shares are owned by institutional investors. Comparatively, 46.2% of shares of all “Commercial physical research” companies are owned by institutional investors. 4.5% of National Research shares are owned by insiders. Comparatively, 16.0% of shares of all “Commercial physical research” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Volatility & Risk
National Research has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, National Research’s rivals have a beta of 3.40, indicating that their average share price is 240% more volatile than the S&P 500.
This is a summary of current ratings and recommmendations for National Research and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|National Research Competitors||178||744||1560||73||2.60|
As a group, “Commercial physical research” companies have a potential upside of 11.24%. Given National Research’s rivals stronger consensus rating and higher possible upside, analysts plainly believe National Research has less favorable growth aspects than its rivals.
National Research rivals beat National Research on 9 of the 13 factors compared.
About National Research
National Research Corporation (NRC) is a provider of analytics and insights that facilitate revenue growth, patient, employee and customer retention and patient engagement for healthcare providers, payers and other healthcare organizations. The Company’s portfolio of subscription-based solutions provides information and analysis to healthcare organizations and payers across a range of mission-critical, constituent-related elements, including patient experience and satisfaction, community population health risks, workforce engagement, community perceptions, and physician engagement. The Company’s clients range from acute care hospitals and post-acute providers, such as home health, long term care and hospice, to numerous payer organizations. The Company derives its revenue from its annually renewable services, which include performance measurement and improvement services, healthcare analytics and governance education services.
Receive News & Ratings for National Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National Research and related companies with MarketBeat.com's FREE daily email newsletter.